Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The drug is being developed at lab scale for the first-line of treatment of Covid-19
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
Subscribe To Our Newsletter & Stay Updated